Corrigendum

The Commentary article by A Briggs et al., ‘Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillation’, which appeared in the February 2022 issue of the Journal of Comparative Effectiveness Research 11(3), 131–138 (2022), was published with an incorrect value in Figures 1A–G.

The forest plots on p.133 were incorrectly labelled Edoxaban 50 mg OD under the “Treatment” header. This should read Edoxaban 60 mg OD. This has now been corrected.

The authors and editors of the Journal of Comparative Effectiveness Research would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.